BioTuesdays

Roth downgrades iRadimed to neutral

IRadimed

Roth Capital Partners downgraded iRadimed (NASDAQ:IRMD) to “neutral” from “buy” with a new price target of $11.50 after the company pre-announced a third quarter miss and reduced its 2016 outlook. The stock closed at $10.77 on Tuesday.

Analyst Chris Lewis writes that the announcement leaves him “incrementally cautious on the near-term pump growth profile and lengthening sales cycle.”

iRadimed is the only provider of non-magnetic intravenous infusion pump systems that are safe for use during MRI procedures.

“While we are still believers in iRadimed’s technologies and market opportunity over the longer-term, we will look for sales cycle normalization, improving new order activity (organic pump growth stability/sustainability), margin visibility, and MRI-monitor regulatory progress / commercial launch, which has been pushed out, to gain higher conviction,” he added.

iRadimed expects 2016 revenues and EPS of $32.9-million to $33.2-million (+4% year-over-year) and 60 cents a share to 63 cents, respectively, versus previous guidance of $39-million to $40-million and 91 cents a share to 93 cents.

“We view iRadimed as a show-me execution story, at this stage,” Mr. Lewis added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.